MWMin Wang

Min Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Min Wang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Copper phosphate nanozymes combat implant-related infections by inducing cuproptosis-like death and inhibiting the two-component system

    by Yaxin Liu, Yang Zheng, Dasheng Tian, Yiwei Sun, Min Wang, Sihai Li, Erxu Tao, Yujing Liao, Fei Huang, Tao Wang, et al.

    Implant-related infections, characterized by recalcitrant biofilm formation, antibiotic resistance, and immune evasion, pose a severe clinical burden in orthopedics due to the limited therapeutic efficacy of conventional approaches. Addressing this challenge requires innovative strategies capable of simultaneously disrupting biofilms and overcoming bacterial defense mechanisms. To address this, we developed flower-like copper phosphate (CuP) nanozymes with dual enzymatic activities (peroxidase- and glutathione peroxidase-like) that synergistically eradicate biofilms for implant-related infections through cuproptosis-like death and two-component system (TCS) inhibition. In vitro antimicrobial experiments demonstrated that CuP nanozymes significantly inhibited and disrupted bacterial biofilms. These CuP nanozymes generate reactive oxygen species (ROS) while depleting glutathione (GSH), disrupting bacterial membranes, and disrupting metabolic processes such as the TCA cycle and glycolysis. Transcriptomic analysis revealed suppressed expression of oxidative phosphorylation genes and quorum-sensing regulators, confirming dual targeting of bacterial viability and communication. In vivo, CuP nanozymes effectively eliminated biofilm infections on implants, reduced inflammatory responses, and demonstrated excellent biocompatibility. By integrating enzymatic ROS amplification, metabolic interference, and TCS inhibition, this strategy offers a transformative approach to combat resistant implant infections, surpassing conventional therapies in both efficacy and safety.


  • Open Access

    Strontium-luteolin nanoparticles promote M2 macrophage polarization and accelerate acute wound healing via immune microenvironment regulation

    by Xiaowen Zheng, Wenqi Wang, Xiaolong Wei, Jianguo Niu, Wei Zhang, Zhenxun Lin, Wei Wei, Shipeng Ning, Min Wang, Xianwen Wang, et al.


  • Open Access

    Extracellular vesicles: a new frontier in diagnosing and treating graft-versus-host disease after allogeneic hematopoietic cell transplantation

    by Peipei Wu, Zhangfei Wang, Yongping Sun, Zhixiang Cheng, Min Wang, Baolong Wang

    Graft-versus-host disease (GvHD) is a prevalent complication following allogeneic hematopoietic stem cell transplantation (HSCT) and is characterized by relatively high morbidity and mortality rates. GvHD can result in extensive systemic damage in patients following allogeneic HSCT (allo-HSCT), with the skin, gastrointestinal tract, and liver frequently being the primary target organs affected. The severe manifestations of acute intestinal GvHD often indicate a poor prognosis for patients after allo-HSCT. Endoscopy and histopathological evaluation remain employed to diagnose GvHD, and auxiliary examinations exclude differential diagnoses. Currently, reliable serum biomarkers for the diagnosis and differential diagnosis of GvHD are scarce. As an essential part of standard transplant protocols, early application of immunosuppressive drugs effectively prevents GvHD. Among them, steroids represent first-line therapeutic agents, and the JAK2 inhibitor ruxolitinib represents the second-line therapeutic agent. Currently, no efficacious treatment modality exists for steroid-resistant aGvHD. Therefore, the diagnosis and treatment of GvHD still face significant medical demands. Extracellular vesicles (EVs) are nanometer to micrometer-scale biomembrane vesicles containing various bioactive components, such as proteins, nucleotides, and metabolites. Distinctive changes in serum-derived EV components occur in patients after allo-HSCT; Hence, EVs are expected to be potential biomarkers for diagnosing and treating GvHD. Furthermore, cell-free therapeutics characterized by EVs derived from mesenchymal stem cells (MSCs) have manifested remarkable therapeutic efficacy in preclinical models and preclinical trials of GvHD. Customized engineered EVs with fewer toxic and side effects for the combined treatment of GvHD hold broad prospects for clinical translation. This review article examines the potential value of translating EVs into clinical applications for the diagnosis and treatment of GvHD. It summarizes the latest advancements and prospects of engineered EVs applying GvHD.